CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

CorMedix Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$7.38+0.12 (+1.65%)

Close on Oct 19, 2026

Market cap: $682.50M
P/E (TTM): 3.6
Dividend yield: –

CorMedix Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	312	43	–	0.07	0.19	0.24	0.28	0.43	0.33	0.22	0.21	0.19	0.00	0	–	–	–	–	–
Cost of Revenue	22	3.03	–	0.00	0.15	0.20	0.37	0.40	0.11	0.37	-0.32	-0.45	-0.20	0	–	–	–	–	–
Gross Profit	276	40	–	0.06	0.04	0.03	-0.09	0.03	0.21	-0.14	-0.11	-0.26	-0.20	0	–	–	–	–	–
Research & Development	19	3.94	13	11	13	13	11	19	24	16	6.28	1.32	1.23	1.14	4.06	5.49	–	–	–
Selling, General & Admin	106	59	36	20	16	14	9.87	8.07	–	–	–	–	–	–	–	–	–	–	–
Selling & Marketing	38	29	18	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	68	30	18	–	–	–	–	8.07	8.65	8.88	10	7.33	3.49	1.86	3.15	3.01	–	–	–
Operating Expenses	126	63	49	31	29	27	21	27	33	25	17	8.65	4.72	3.00	7.21	8.51	–	–	–
Total Costs & Expenses	–	–	–	–	3.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	150	-22	-49	-31	-29	-27	-21	-27	-33	-25	-17	-8.90	-4.92	-3.00	-7.21	-8.51	–	–	–
Interest Expense	2.78	0.04	0.03	0.03	0.02	0.03	0.79	0.00	0.01	0.00	0.00	0.00	1.44	0.38	0	3.09	–	–	–
Interest & Investment Income	3.85	2.58	2.68	0.33	0.01	0.12	0.32	0.04	0.11	0.13	0.06	0.00	0.00	0.00	0.01	0.02	–	–	–
Other Non-Operating Income	-0.13	3.03	2.62	0.34	-0.02	0.02	-0.49	0.03	-0.09	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	0.00	0	0.01	0.01	-0.02	0	–	–	–	–	–	–	–
Pretax Income	150	-19	-46	-30	-29	-27	-21	-27	-33	-25	-18	-20	-9.13	-3.38	-7.17	-11	–	–	–
Income Tax Expense	-13	-1.40	–	-0.59	-1.25	-5.17	-5.06	–	–	–	–	–	0	0	-0.49	-0.28	–	–	–
Income from Continuing Operations	1.70	–	-46	-30	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-28	-22	-16	–	–	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	–	28	22	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	163	-18	-46	-30	-28	-22	-16	-27	-33	-25	-18	-20	-9.13	-3.38	-6.67	-11	-8.12	-9.00	-7.24
Net Income to Common	–	–	–	–	–	-22	-44	-27	–	-25	-18	-21	-9.52	-3.38	–	–	–	–	–
EPS (Basic)(per share)	2.25	-0.30	-0.91	-0.74	-0.75	-0.77	-1.80	-1.51	-0.60	-0.65	-0.58	-0.96	-0.69	-0.30	-0.58	-1.15	–	–	–
EPS (Diluted)(per share)	2.04	-0.30	-0.91	-0.74	-0.75	-0.77	-1.80	-1.51	-0.60	-0.65	-0.58	-0.96	-0.69	-0.30	-0.58	-1.15	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.07	0.06	51	40	38	29	24	18	55	38	31	21	14	11	11	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	0.08	0.06	51	40	38	29	24	18	55	38	31	21	14	11	11	–	–	–	–
Net Interest Income	–	1.40	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 82.8%
Operating margin: 47.0%
Net margin: 40.5%
Return on equity, FY2025: 66.6%

Financial strength

Current ratio: 2.56
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 137.0%

Valuation

P/E ratio: 3.6
Price to sales: 1.48
Price to book: 1.48
Dividend yield: –